Ryan James Timothy Patrick 4

What Happened Ryan James Timothy Patrick, BioNTech's Chief Legal Officer and Chief Business Officer, was granted two equity awards on May 12, 2026. The filing shows 12,586 derivative shares as an option grant (exercise price €89.38) and 10,069 performance share units (PSUs), for a total of 22,655 derivative awards. These are grants (transaction code A) reported on a Form 4 and were filed the next day (May 13, 2026).

Key Details

• Date of grant: 2026-05-12; Form 4 filed 2026-05-13 (timely).
• Awards: 12,586 stock options (exercise price €89.38, subject to adjustment) and 10,069 PSUs.
• Vesting/exercisability: Options and PSUs vest annually in equal installments over four years beginning on the first anniversary; options become exercisable four years after grant, subject to performance and other conditions.
• Settlement: Awards may be settled in ordinary shares, ADSs and/or cash at the supervisory board’s election; each PSU is economically equivalent to one ordinary share and may vest based on performance versus the Nasdaq Biotechnology Index (or successor index).
• Shares owned after transaction: not specified in the excerpt provided.
• Filing timeliness: filed one day after the grant date; no late-filing indication in the provided data.

Context These were compensation awards, not open-market purchases or sales. Options have a specified strike (€89.38) and include an adjustment provision limiting ADS trading price to 800% of grant-date exercise price at exercise; PSUs are performance-based and only convert to value (shares/ADSs/cash) if performance targets and continued service are met. Such grants are routine executive compensation and do not by themselves signal immediate buying or selling of company stock.